Molecular Partners AG (MOLN)Healthcare | Biotechnology | Schlieren, Switzerland | NasdaqGS
4.50 USD
-0.15
(-3.276%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.52 +0.02 (0.444%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:19 a.m. EDT
The immediate outlook remains neutral due to a lack of clear directional momentum, despite a recent price recovery that has lifted the stock above its 50-day average. However, the long-term investment case is severely compromised by a catastrophic multi-year decline; the asset has lost over 80% of its value since 2021, with the most recent annual period showing a sharp drop of nearly 45%. This persistent downward trajectory suggests the market has fundamentally rejected the current business model, rendering any 'value' narrative dangerous rather than attractive. Furthermore, the company is burning significant cash with negative free cash flow and no history of paying dividends, leaving investors exposed to dilution without any income floor. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.024041 |
| AutoTheta | 0.024323 |
| AutoARIMA | 0.024728 |
| MSTL | 0.025611 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 53% |
| H-stat | 0.35 |
| Ljung-Box p | 0.067 |
| Jarque-Bera p | 0.718 |
| Excess Kurtosis | -0.38 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.196 |
| Market Cap | 172,373,568 |
| Forward P/E | -26.60 |
| Beta | 0.68 |
| Website | https://www.molecularpartners.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.18421054 |
| Address1 | Wagistrasse 14 |
| All Time High | 32.04 |
| All Time Low | 3.32 |
| Ask | 4.01 |
| Ask Size | 1 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 1,930 |
| Average Daily Volume3 Month | 4,577 |
| Average Volume | 4,577 |
| Average Volume10Days | 1,930 |
| Beta | 0.677 |
| Bid | 3.91 |
| Bid Size | 1 |
| Book Value | 1.8977607 |
| City | Schlieren |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.5 |
| Current Ratio | 7.274 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.67 |
| Day Low | 4.5 |
| Debt To Equity | 5.196 |
| Earnings Call Timestamp End | 1,741,345,140 |
| Earnings Call Timestamp Start | 1,741,345,140 |
| Earnings Timestamp | 1,787,661,000 |
| Earnings Timestamp End | 1,787,661,000 |
| Earnings Timestamp Start | 1,787,661,000 |
| Ebitda | -50,850,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.114 |
| Enterprise Value | 107,485,568 |
| Eps Current Year | -1.11065 |
| Eps Forward | -0.16918556 |
| Eps Trailing Twelve Months | -1.68 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 41 44 755 77 07 |
| Fifty Day Average | 4.0759 |
| Fifty Day Average Change | 0.42409992 |
| Fifty Day Average Change Percent | 0.10405062 |
| Fifty Two Week Change Percent | 18.421055 |
| Fifty Two Week High | 5.36 |
| Fifty Two Week High Change | -0.86000013 |
| Fifty Two Week High Change Percent | -0.16044778 |
| Fifty Two Week Low | 3.53 |
| Fifty Two Week Low Change | 0.97 |
| Fifty Two Week Low Change Percent | 0.27478755 |
| Fifty Two Week Range | 3.53 - 5.36 |
| Financial Currency | CHF |
| First Trade Date Milliseconds | 1,623,850,200,000 |
| Float Shares | 20,712,408 |
| Forward Eps | -0.16918556 |
| Forward P E | -26.598015 |
| Free Cashflow | -27,040,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 134 |
| Fullday Change | -0.1524 |
| Fullday Change Percent | -3.27573 |
| Fullday Price | 4.52 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -35,566,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.093830004 |
| Implied Shares Outstanding | 38,305,237 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-16 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. |
| Long Name | Molecular Partners AG |
| Market | us_market |
| Market Cap | 172,373,568 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_32677064 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -51,187,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 178,404,641 |
| Number Of Analyst Opinions | 5 |
| Open | 4.67 |
| Operating Cashflow | -46,113,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 41 44 755 77 00 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 0.44444403 |
| Post Market Price | 4.52 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 4.6524 |
| Price Eps Current Year | -4.0516815 |
| Price Hint | 4 |
| Price To Book | 2.3712156 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.054 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | -0.15240002 |
| Regular Market Change Percent | -3.275729 |
| Regular Market Day High | 4.67 |
| Regular Market Day Low | 4.5 |
| Regular Market Day Range | 4.5 - 4.67 |
| Regular Market Open | 4.67 |
| Regular Market Previous Close | 4.6524 |
| Regular Market Price | 4.5 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 1,534 |
| Return On Assets | -0.32275 |
| Return On Equity | -0.61967 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 38,305,237 |
| Shares Percent Shares Out | 0.0 |
| Shares Short | 187 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,733 |
| Short Name | Molecular Partners AG |
| Short Percent Of Float | 0.0 |
| Short Ratio | 0.21 |
| Source Interval | 15 |
| Symbol | MOLN |
| Target High Price | 16.866428 |
| Target Low Price | 3.7452118 |
| Target Mean Price | 10.671691 |
| Target Median Price | 11.905351 |
| Total Cash | 67,930,000 |
| Total Cash Per Share | 1.773 |
| Total Debt | 3,042,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.68 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.236585 |
| Two Hundred Day Average Change | 0.26341486 |
| Two Hundred Day Average Change Percent | 0.062176224 |
| Type Disp | Equity |
| Volume | 1,534 |
| Website | https://www.molecularpartners.com |
| Zip | 8,952 |